Evidence map›Paper›PMID 35743606›Full record

ArticleJournal of clinical medicine2022

Association of the

Izabela Uzar, Anna Bogacz, Elżbieta Sowińska-Przepiera, Krzysztof Piątek, Filip Przerwa, Marlena Wolek, Bogusław Czerny

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Association between the aromatase (Archives of endocrinology and metabolism · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Izabela UzarDepartment of Pharmacology and Pharmacoeconomics, Pomeranian Medical University, 71-230 Szczecin, Poland.
Anna BogaczDepartment of Stem Cells and Regenerative Medicine, Institute of Natural Fibers and Medicinal Plants, 62-064 Plewiska, Poland.ORCID 0000-0001-5455-8315
Elżbieta Sowińska-PrzepieraDepartment of Endocrinology, Metabolic Diseases and Internal Diseases, Pomeranian Medical University, 71-252 Szczecin, Poland.
Krzysztof PiątekDepartment of Gynecology and Obstetrics, Collegium Medicum, University of Zielona Góra, 65-001 Zielona Góra, Poland.
Filip PrzerwaDepartment of Pharmacology and Pharmacoeconomics, Pomeranian Medical University, 71-230 Szczecin, Poland.
Marlena WolekDepartment of Stem Cells and Regenerative Medicine, Institute of Natural Fibers and Medicinal Plants, 62-064 Plewiska, Poland.
Bogusław CzernyDepartment of Pharmacology and Pharmacoeconomics, Pomeranian Medical University, 71-230 Szczecin, Poland.
Institute of Natural Fibres and Medicinal Plants · PLPomeranian Medical University · PLUniversity of Zielona Góra · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperandrogenism is the most common endocrine disorder in women, characterized by an imbalance of normal estrogen and androgen levels in the blood. Androgens play an important role in the female body because they influence bone mineral density (BMD), body mass composition, muscle mass, mental state, and the regulation of sexual function. The reduced activity of aromatase, due to mutations in the

Indexed as

bone metabolismCYP19A1gene polymorphismhyperandrogenism

Identifiers

PMID35743606
PMCPMC9224995
OpenAlexW4283218525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.